MediciNova (MNOV) Competitors $1.34 -0.02 (-1.47%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.02 (+1.42%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. IMMP, TKNO, SCPH, ALLO, SGMT, SOPH, AARD, FENC, TLSA, and GALTShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Prima BioMed (IMMP), Alpha Teknova (TKNO), scPharmaceuticals (SCPH), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Its Competitors Prima BioMed Alpha Teknova scPharmaceuticals Allogene Therapeutics Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics Prima BioMed (NASDAQ:IMMP) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Do institutionals & insiders have more ownership in IMMP or MNOV? 2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 13.6% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, IMMP or MNOV? MediciNova has lower revenue, but higher earnings than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M47.41-$28.01MN/AN/AMediciNova$134.60K488.32-$11.04M-$0.25-5.36 Do analysts rate IMMP or MNOV? Prima BioMed currently has a consensus price target of $7.00, indicating a potential upside of 321.69%. MediciNova has a consensus price target of $7.00, indicating a potential upside of 422.39%. Given MediciNova's stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Prima BioMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media favor IMMP or MNOV? In the previous week, MediciNova had 4 more articles in the media than Prima BioMed. MarketBeat recorded 5 mentions for MediciNova and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.87 beat MediciNova's score of 1.12 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive MediciNova Positive Which has more volatility & risk, IMMP or MNOV? Prima BioMed has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Is IMMP or MNOV more profitable? Prima BioMed's return on equity of 0.00% beat MediciNova's return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A MediciNova N/A -23.12%-21.85% SummaryMediciNova beats Prima BioMed on 8 of the 13 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.73M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-5.3621.2230.8326.39Price / Sales488.32206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book1.258.0710.106.62Net Income-$11.04M-$54.08M$3.26B$265.42M7 Day Performance2.29%3.94%3.90%3.58%1 Month Performance-8.22%3.02%3.73%0.46%1 Year Performance-8.22%6.84%37.68%19.41% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova2.417 of 5 stars$1.34-1.5%$7.00+422.4%+7.1%$65.73M$134.60K-5.3610News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeIMMPPrima BioMed1.5114 of 5 stars$1.78+2.9%$7.00+293.3%-29.3%$253.94M$5.14M0.002,021Positive NewsUpcoming EarningsGap UpTKNOAlpha Teknova2.4029 of 5 stars$4.41-6.0%$10.00+126.8%-9.5%$250.99M$37.74M-10.50240Positive NewsSCPHscPharmaceuticals4.2589 of 5 stars$4.78+3.9%$14.00+192.9%+6.1%$245.17M$36.33M-2.6430News CoverageAnalyst DowngradeALLOAllogene Therapeutics2.8374 of 5 stars$1.09-0.9%$8.44+674.7%-58.6%$244.07M$20K-0.98310SGMTSagimet Biosciences2.9664 of 5 stars$7.55-1.6%$25.67+240.0%+127.3%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.9365 of 5 stars$3.49+0.6%$8.00+129.2%-9.6%$234.50M$65.17M-7.93520Positive NewsAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018FENCAdherex Technologies1.9143 of 5 stars$8.20-1.9%$13.33+62.6%+48.6%$232.52M$47.54M-19.5210Analyst RevisionTLSATiziana Life Sciences0.8404 of 5 stars$1.89-4.1%N/A+54.5%$230.19MN/A0.008GALTGalectin Therapeutics1.8863 of 5 stars$3.90+9.2%$6.00+53.8%+71.2%$228.70MN/A-6.099 Related Companies and Tools Related Companies IMMP Competitors TKNO Competitors SCPH Competitors ALLO Competitors SGMT Competitors SOPH Competitors AARD Competitors FENC Competitors TLSA Competitors GALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access